preoperative pembrolizumab with concurrent chemoradiotherapy
Showing 26 - 50 of 8,460
Glioblastoma Multiforme Trial in Saint Louis (drug, procedure, radiation)
Active, not recruiting
- Glioblastoma Multiforme
- Disulfiram
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 22, 2022
Brain Tumor Trial (Propofol, Sevoflurane)
Recruiting
- Brain Tumor
-
Kaohsiung, TaiwanKaohsiung Medical University Chung-Ho Memorial Hospital
Dec 15, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Sintilimab, Capecitabine)
Recruiting
- Nasopharyngeal Carcinoma
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 5, 2022
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Dec 6, 2022
Small Cell Lung Cancer Trial in Worldwide (biological, drug, radiation)
Recruiting
- Small Cell Lung Cancer
- Pembrolizumab 200 mg
- +8 more
-
Chandler, Arizona
- +170 more
Feb 2, 2023
Lung Cancer, Brain Tumor, Liver Cancer Trial in Kaohsiung (Propofol, Sevoflurane)
Not yet recruiting
- Lung Cancer
- +3 more
-
Kaohsiung, TaiwanKaohsiung Medical University Chung-Ho Memorial Hospital
Jul 4, 2023
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) Trial in
Recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- +2 more
- pembrolizumab
- +7 more
-
Long Beach, California
- +158 more
Jan 19, 2023
Head and Neck Squamous Cell Carcinoma Trial in Chongqing (Camrelizumab, Concurrent cisplatin chemo, Intensity-modulated
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Camrelizumab
- +2 more
-
Chongqing, Chongqing, ChinaChongqing University Cancer Hospital
Jan 16, 2022
Rectal Cancer Trial in Korea, Republic of (radiation, drug, procedure)
Recruiting
- Rectal Cancer
- short-course radiotherapy
- +3 more
-
Daegu, Korea, Republic of
- +8 more
Jan 8, 2023
Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)
Not yet recruiting
- Locally Advanced Rectal Cancer
- capecitabine
- +3 more
-
Beijing, China
- +1 more
Sep 21, 2023
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Toripalimab, Paclitaxel-albumin, Nedaplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Oct 25, 2022
Cervical Cancer Trial in Tianjin (Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy)
Recruiting
- Cervical Cancer
- Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute&Hospital
Oct 19, 2021
Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer Trial in Guangzhou (PD-1 inhibitor, concurrent
Recruiting
- Anal Canal Cancer Stage III
- +3 more
- PD-1 inhibitor
- concurrent chemoradiotherapy
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated Hospital of Sun Yat-sen University
May 10, 2022
Urinary Bladder Tumors Trial in Worldwide (Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy
Recruiting
- Urinary Bladder Neoplasms
- Pembrolizumab
- +8 more
-
Washington, District of Columbia
- +120 more
Jan 19, 2023
Esophageal Squamous Cell Carcinoma, Esophagectomy, Radiotherapy Trial (Since the data were collected retrospectively, there were
Completed
- Esophageal Squamous Cell Carcinoma
- +3 more
- Since the data were collected retrospectively, there were no interventions
- (no location specified)
Oct 31, 2022
Oropharyngeal Squamous Cell Carcinoma (SCC) Trial run by the National Cancer Institute (NCI) (PRGN-2009, Pembrolizumab)
Not yet recruiting
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- PRGN-2009
- Pembrolizumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 22, 2023
Locally Advanced Nasopharyngeal Carcinoma Trial in Guangzhou (2 cycles induction chemo, 3 cycles induction chemo)
Recruiting
- Locally Advanced Nasopharyngeal Carcinoma
- 2 cycles induction chemotherapy
- 3 cycles induction chemotherapy
-
Guangzhou, Other (Non U.s.), ChinaFirst Affiliated Hospital, Sun Yat-Sen University
May 6, 2023
Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Oct 25, 2022
Esophageal Cancer Trial (Hypofractionated radiotherapy)
Not yet recruiting
- Esophageal Cancer
- Hypofractionated radiotherapy
- (no location specified)
Jan 18, 2023
Ovarian Cancer Trial in Kaohsiung (Propofol 1%, Sevoflurane/Ultane)
Recruiting
- Ovarian Cancer
- Propofol 1%
- Sevoflurane/Ultane
-
Kaohsiung, TaiwanKaohsiung Medical University Chung-Ho Memorial Hospital
Nov 29, 2022
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction Trial in Colorado Springs, Lone Tree (Sequential FLOT
Recruiting
- Adenocarcinoma Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Sequential FLOT followed by chemoradiation
-
Colorado Springs, Colorado
- +2 more
Feb 22, 2022
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma
- Carrelizumab
- +3 more
-
Nanjing, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Rectal Cancer Patients Based on ctDNA-MRD Technology
Recruiting
- Rectal Adenocarcinoma
- +3 more
- MRD detection
-
Guangzhou, Guangdong, ChinaWeiWei Xiao
Jul 31, 2023